Digital Breast Cancer Aftercare Faces the Real Test of Implementation
Breast cancer aftercare does not fail only at the level of protocol design. It also fails, or succeeds, in the ordinary friction of clinic visits, patient preferences, staff workflow, and whether a complex plan can actually be delivered as intended. The BETTER-CARE programme was built around that problem: a digitally supported, needs-adapted, and risk-adapted complex intervention for breast cancer aftercare, with this mixed-methods process evaluation examining how the model was implemented and how it was experienced by both patients and healthcare professionals.
The study sits in a setting where the burden of disease is substantial. In Germany, approximately 70,000 people were diagnosed with breast cancer in 2022, and it remains the most common cancer among women. Average age at onset in women is 65 years, which places aftercare squarely in a population that often carries multimorbidity, competing health priorities, and varying digital comfort. In that context, a one-size-fits-all follow-up plan is unlikely to meet the full range of survivorship needs.
A process evaluation matters because even an intervention with a sound clinical rationale can drift once it enters routine care. Fidelity, acceptability, and feasibility become the decisive variables. In BETTER-CARE, the mixed-methods design was chosen to capture both the operational side of implementation and the human side of care delivery. Semistructured interviews included both patients and healthcare professionals, allowing the evaluation to reflect perspectives from the people receiving the intervention and the people expected to deliver it.
Fidelity, Workflow, and the Limits of Real-World Delivery
The intervention was assessed through a process lens rather than as a pure efficacy trial. That distinction is important because a digitally enabled aftercare model depends on more than the content of its recommendations. It depends on whether patients can engage with the digital component, whether clinicians can integrate the workflow into routine practice, and whether the intervention remains consistent across centers and regions.
The evaluation specifically sought to examine fidelity. In practical terms, fidelity asks whether the intervention was delivered as planned, or whether local adaptation, staffing constraints, or uneven engagement changed the experience on the ground. For a needs-adapted and risk-adapted programme, fidelity has particular weight: if the intervention is meant to tailor follow-up intensity to patient needs and risk, then implementation drift can blur the very mechanism that makes the programme clinically interesting.
One sentence captures the operational challenge: complex survivorship care is easy to specify and hard to standardize.
Voices from Patients and Clinicians Were Central to the Design
Including both patients and healthcare professionals in the semistructured interviews strengthened the evaluation by widening the lens beyond a single stakeholder group. Patients can speak to usability, burden, clarity, and whether the programme feels responsive to the realities of recovery and follow-up. Clinicians can describe workload, coordination demands, and whether digital tools help or complicate the cadence of aftercare.
That dual perspective is especially relevant in breast cancer survivorship, where care often extends beyond surveillance for recurrence and into symptom management, psychosocial support, rehabilitation, and long-term risk monitoring. A risk-adapted model only works if it can match the intensity of follow-up to clinical need without overwhelming the system or underserving patients who require closer attention.
The mixed-methods design offered a broad view of how BETTER-CARE functioned in practice, but the article’s own limitations show how difficult it is to reach complete representativeness in a multicenter implementation study. The plan was to interview one patient and one healthcare professional per centre. That goal was not achieved in all intervention regions, creating the possibility of selection bias and leaving open the chance that the sample did not capture the full diversity of perspectives.
What the Study Could and Could Not Capture
Selection bias matters here because process evaluations rely on qualitative depth as much as breadth. If certain centers contributed fewer voices than planned, the resulting narrative may overrepresent the views of sites with stronger engagement, more favorable implementation conditions, or more available staff. A process evaluation can still be useful under those circumstances, but the reader should interpret the findings as a partial map rather than a complete census of experience.
The study also did not return transcripts to participants for comment or correction. In qualitative research, that omission limits one form of participant validation and may reduce confidence that interview records fully reflected the intended meaning of respondents’ statements. The absence of transcript review does not invalidate the work, but it does narrow the safeguards around interpretive accuracy.
Those limitations are not trivial in a programme built on personalization. If the intervention is designed to adapt to patient needs and risk, then implementation heterogeneity is not just a logistical concern; it is part of the clinical question. The way a digitally supported aftercare pathway is delivered may determine whether it becomes an efficient extension of oncology follow-up or simply another layer of complexity.
Why Process Evaluation Still Matters in Survivorship Care
Breast cancer aftercare increasingly depends on systems that can do more than schedule visits. They must triage risk, support communication, and align support with changing patient needs over time. Digital support may help organize those tasks, but it also introduces new demands: usability, acceptance, interoperability, and the need for clinicians to trust the workflow enough to use it consistently.
A process evaluation cannot prove clinical benefit on its own. It can show whether the intervention was carried out with enough fidelity to make future outcome data interpretable, and whether patients and professionals perceived the model as workable in practice. In a complex survivorship programme, that information is not secondary. It is the bridge between design and effectiveness.
The remaining questions are operational rather than abstract: how consistently can a digitally supported, needs-adapted aftercare pathway be delivered across centers, and how broad was the range of views that ultimately shaped the evaluation? Those are the issues that determine whether BETTER-CARE can move from a carefully planned model to routine breast cancer follow-up with enough consistency to matter at the bedside.